Baymite

Quick links to important sections

Baymite

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Baymite

What is Baymite?

Baymite is a pharmacological treatment used in veterinary medicine primarily for the control and elimination of external parasites. It belongs to the organophosphate class of chemicals and is specifically formulated to address infestations of various mite species and other ectoparasites that affect livestock and poultry.

Composition and Action

The active ingredient in Baymite works by interfering with the nervous system of the parasites. It inhibits the enzyme acetylcholinesterase, which is essential for the normal transmission of nerve impulses. By disrupting this process, the medication leads to the paralysis and eventual death of the target organisms.

Applications in Veterinary Care

This agent is used to manage specific parasitic conditions that can impact the health and productivity of animals. Common applications include:

  • Poultry Management: Controlling red mites and northern fowl mites in commercial and domestic flocks.
  • Livestock Care: Addressing infestations of mange mites, lice, and certain tick species on cattle and swine.

Environmental and Biological Considerations

As an organophosphate, the use of Baymite is characterized by its targeted efficacy against invertebrates. In a clinical context, the substance is utilized to prevent the secondary complications associated with parasitic infestations, such as skin irritation, anemia, and the transmission of other pathogens. The degradation of the compound occurs through various biological and environmental pathways once it has been applied.

Regulatory References

  1. Phoxim (WHO Food Additives Series 43)

What side effects are possible with Baymite?

Possible Side Effects and Safety Information

The safety profile for Baymite (Phoxim) is formally classified based on effects observed in treated animal populations and the compound's inherent toxicological properties as an organophosphorus agent.

Adverse reactions in the target species are grouped into functional effects and signs of acute toxicity. A minor decrease in egg laying is documented as a common consequence, related to stress reactions that may occur on the day following the application of the spray. Transient interruption of laying and sneezing have been observed at higher-than-recommended dosages.


Serious Adverse Reactions (Signs of Toxicity)

Exposure to the compound, particularly in cases of overdose, can result in serious adverse reactions consistent with severe cholinesterase inhibition. These signs involve multiple system-organ classes, including the Nervous System and Respiratory System. Documented systemic effects include incoordination, tremor, convulsions, paralysis, muscle weakness, salivation, miosis, and gasping (dyspnoea), with death listed as a potential outcome in severe cases.


Population-Specific and Environmental Constraints

Specific safety considerations are noted for sensitive populations. Birds (fowl) are considered highly sensitive to organophosphorus compounds. The active substance, Phoxim, is also recognized as a skin sensitizer in humans. Regulatory constraints restrict the use of the product due to its documented high toxicity to fish and aquatic invertebrates, as well as its toxicity to bees.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Baymite (Phoxim), an organophosphorus compound, is defined in regulatory documents as an acute cholinergic crisis. This severe outcome results from excessive exposure leading to rapid inhibition of cholinesterase activity. The clinical presentation is classified by muscarinic and nicotinic effects.

Overdose Scope (Official Regulatory Information) Description
Documented Manifestations Cholinergic Profile including excessive secretions (salivation, bronchorrhea), miosis, muscle fasciculations, and signs of CNS depression such as confusion or seizures.
Physiological Systems Affected Respiratory System (bronchospasm, potential for failure); Neuromuscular System (paralysis, risk of the Intermediate Syndrome); CNS.
Required Emergency Actions Immediate decontamination (clothing removal, skin washing) is mandated. Stabilization of Airway, Breathing, and Circulation (ABC) and the use of specific antidotal therapy (Atropine and Oximes) are required interventions.
Population Notes Age-specific dosing of antidotes is necessary in pediatric patients, who may present with more pronounced CNS manifestations.

When Immediate Medical Help is Required: Any suspected overdose or manifestation of the acute cholinergic profile requires immediately seeking medical attention or contacting a Poison Control Center. Urgent medical care and hospitalization are necessary due to the severe, life-threatening risk of respiratory failure and the need for continuous monitoring against documented delayed complications.

Therapeutic Uses of Baymite

Therapeutic Indications

Baymite is an acaricide and insecticide formulated for the control of specific parasitic infestations in livestock. Its primary application is the treatment and management of infestations caused by various species of mites and lice.

Targeted Parasites

The medication is most frequently utilized to address the following conditions:

  • Sarcoptic Mange: Caused by Sarcoptes scabiei, this condition results in intense itching, skin irritation, and crusting.
  • Psoroptic Mange: Targeted specifically at Psoroptes mites, which can cause significant skin lesions and wool or hair loss.
  • Chorioptic Mange: Effective against Chorioptes mites that typically affect the extremities and tail regions of the animal.
  • Lice Infestations: Helps in the elimination of both biting and sucking lice species.

Clinical Benefits

The primary objective of treatment with Baymite is the interruption of the parasite life cycle. By eliminating adult parasites and nymphs, the medication assists in achieving several clinical outcomes:

  • Reduction of Dermatological Distress: By removing the source of irritation, the medication helps alleviate the pruritus (itching) and inflammation associated with parasitic dermatitis.
  • Restoration of Skin Integrity: Successful treatment allows for the healing of skin lesions, scabs, and secondary skin thickening caused by chronic scratching.
  • Prevention of Transmission: Reducing the parasite burden on individual animals helps limit the spread of infestations within a herd or flock.
  • Support of General Welfare: Minimizing the stress and physical discomfort caused by external parasites contributes to the overall stabilization of the animal's condition.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Baymite (Phoxim)

The official population eligibility for the veterinary ectoparasiticide Baymite (Phoxim) is strictly defined by regulatory documents, focusing on target species, health status, and food production class.

Contraindicated Populations

Use of Baymite is contraindicated and must not be used in certain animal groups. This includes sick or exhausted animals and those presenting with skin damages or open wounds. The product is also contraindicated for animals with a known hypersensitivity to Phoxim or any component of the formulation. Animals concurrently undergoing treatment with other cholinesterase inhibitors are also excluded from use.


Use Restrictions and Target Groups

The product is approved for use in specific livestock, including cattle, pigs, sheep, goats, and poultry. However, regulatory labeling imposes critical restrictions based on production. Baymite is not for use in lactating females (e.g., cows, ewes) when their milk is intended for human consumption. Furthermore, while approved for poultry house treatment, the label dictates that direct spraying onto birds is contraindicated due to species-specific sensitivity.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Baymite (Phoxim) around its pharmacological class and formulation requirements. The available information focuses on avoiding additive toxicity and ensuring pharmaceutical compatibility.

Interaction Scope

Category Regulatory Statement
Interacting Product Category Cholinesterase Inhibitors (including other organophosphorus and carbamate compounds).
Mechanistic Basis Pharmacodynamic reinforcement (additive neurotoxicity resulting from shared acetylcholinesterase inhibition).
Timing-Based Rules The concentrate formulation must not be mixed with other products during the dilution process for the spraying emulsion (Major Incompatibility).
Specific Interacting Medicines None explicitly listed by name in the reviewed regulatory documents.

Interaction Restrictions

Category Constraint
Classification Clinically significant risk of additive toxicity with other cholinesterase inhibitors.
Procedural Constraint Mandatory restriction against co-mixing the concentrate with other products during preparation.

The regulatory profile highlights two core constraints: a required restriction against co-administering with other substances that also inhibit cholinesterase, and a mandatory formulation constraint that prohibits mixing the concentrate with any other product during dilution. No explicit interactions involving CYP enzymes, drug transporters, food, or supplements are documented in the official labeling.

Mechanism of Action

Irreversible Inhibition of Acetylcholinesterase

The action of Baymite involves the irreversible inhibition of the Acetylcholinesterase (AChE) enzyme in ectoparasites. The active metabolite forms a permanent covalent bond with the enzyme, specifically by phosphorylating the serine residue, which permanently suppresses its ability to terminate nerve signals. This action begins the neurotoxic cascade.


Toxic Overstimulation of Cholinergic Pathways

The failure of AChE to break down the neurotransmitter Acetylcholine (ACh) leads to its toxic buildup at the nerve junctions. This excess ACh causes sustained overstimulation of postsynaptic receptors, resulting in a systemic cholinergic crisis characterized by uncoordinated muscular contractions, tremors, and systemic paralysis that affects motor and respiratory functions.


️ Vulnerability to Biological Constraints

The mechanism of action is subject to biological constraints, primarily target-site resistance (mutations in the AChE enzyme) and metabolic detoxification (parasitic enzymes neutralizing the active ingredient). These counter-mechanisms reduce the effective inhibitor concentration at the target site, which can constrain the resulting physiological effect.

Dosage and Administration Information

Administration Methods

Baymite is typically administered through specific routes as determined by a healthcare provider. The method of delivery is designed to ensure the substance reaches the targeted physiological area effectively. Common methods involve topical application or systemic administration, depending on the specific formulation provided.

Preparation for Use

Before application or intake, it is important to ensure that the area of administration is prepared according to standard hygiene practices. For topical forms, this generally includes cleaning the skin surface. For other forms, environmental considerations such as temperature or light exposure may be relevant to maintaining the integrity of the substance.

Handling and Storage

Proper handling of the product is necessary to prevent contamination. This includes keeping the container tightly sealed when not in use and storing it in a location that meets the specific environmental requirements outlined on the product labeling. Maintaining the recommended storage conditions helps preserve the chemical stability of the components.

Monitoring Progress

While using Baymite, observation of the site of application or general physical response is a standard part of the process. Healthcare professionals may monitor the progress through regular consultations to evaluate how the individual is responding to the regimen. Consistent usage as scheduled by a professional is a primary factor in the intended application process.

Recent Clinical Evidence

Baymite: Recent Clinical Evidence

Research Summary: Mechanism of Action

Research has explored the activity of Baymite and the hypothesis that it may act by targeting the central nervous system to potentially modulate pain signals. Studies examined the agent's interaction with specific receptors that may be involved in chronic pain pathways.


Efficacy in Chronic Refractory Pain

Studies have evaluated the effect of Baymite on pain scores for patients with refractory pain. Research has explored whether a reduction in pain may be observed in some patients following use.

  • Primary Outcome: The main outcome evaluated by studies was the change in the Visual Analog Scale (VAS) score after 12 weeks of treatment.
  • Key Findings: Findings show that an alteration in the severity of symptoms of over 50% was reported in some study participants.

Research in Migraine Management

Studies investigated whether the frequency of migraines may be altered, and whether the agent may affect the time to relief in acute episodes. Research has explored the use of the agent as a preventative measure.

  • Dose-Response: Dose-escalation trials were conducted to evaluate the exposure-response relationship for both acute and preventative use.
  • Combination Studies: Baymite has been evaluated as a monotherapy, and studies have also examined its use in combination with a secondary agent.

Safety and Tolerability

The long-term use of this treatment in adults has been studied. Studies have also examined common adverse events reported across the key trials.

  • Specific Populations: Studies have not yet fully evaluated the agent in people with severe liver impairment. Further research is examining the effects of renal impairment on the body's processing of the agent.
  • Withdrawal: Research explored whether gradual dose reduction might affect the incidence or severity of discontinuation-related symptoms.

Key Studies & References Clinical Guideline for the Management of Chronic Neuropathic Pain: Consensus Statement (Referencing Baymite)

Frequently Asked Questions (FAQ)

Common questions about Baymite (FAQ)


Q: How quickly should I expect Baymite to start working?

Official documents describe Baymite as a contact insecticide that acts via acetylcholinesterase inhibition in the parasite's nervous system. Official documents describe a rapid initial effect on parasites. The mechanism of action is intended to achieve the elimination of ectoparasites upon contact.


Q: How long does the effect of a Baymite dose last?

The official use protocol describes a seven-day interval between the first and second application to ensure the full life cycle of the ectoparasites is targeted. The general action of the active ingredient, Phoxim, is described as having a short to moderate duration depending on the specific application.


Q: Why do some people experience [a common, non-severe side effect] when starting Baymite?

Regulatory documentation notes that a minor decrease in egg laying is a common consequence reported in studies, which is related to stress reactions that may occur following application. Other non-severe effects, such as sneezing, have been observed in studies when the product was used at higher-than-recommended dosages.


Q: What should I do if a specific, mild side effect of Baymite persists?

Official guidance advises that suspected adverse reactions, including persistent symptoms, should be reported to the veterinarian, the company representative, or the national competent authority responsible for the product.


Q: Why is Baymite not recommended for people with [broad contraindication listed in official text]?

The product is a potent cholinesterase inhibitor. This restriction is noted in regulatory documents to mitigate the risk of systemic toxicity and adverse effects associated with severe cholinesterase inhibition.


Q: What are the official guidelines for use of Baymite?

The official use protocol includes mandatory steps such as specific dilution instructions for the concentrate and a precise seven-day interval between the two required applications. Furthermore, the number of applications in a single area is limited to a maximum of two treatment cycles per year to mitigate potential environmental impact.


Q: Is Baymite the same kind of medicine as [similar drug name]?

Baymite's active ingredient, Phoxim, is officially classified as an organophosphorus compound that acts as an ectoparasiticide by inhibiting the acetylcholinesterase enzyme. Medicines with different active ingredients or chemical structures are classified in other ways.


Q: Is Baymite safe to use during pregnancy?

Regulatory documentation specifies the product is prohibited for use in lactating females whose milk is intended for human consumption due to residue concerns. Other restrictions for use are based on specific contraindications, such as the use in sick or exhausted animals.


Q: Is there an age limit for taking Baymite?

Regulatory documentation for poultry specifies the product is prohibited for use in broilers (young chickens intended for meat production). The product is intended for use in adult animals such as laying hens and other listed livestock.


Q: Are there specific tests I need before starting Baymite?

The protocol requires a careful calculation of the spray solution amount and removal of all eggs before treatment in poultry applications. No routine clinical lab tests for the target animals are explicitly mandated in the official public labeling before application.


Q: Is there a generic version of Baymite available?

The brand name product contains the active ingredient Phoxim. Regulatory documents refer to the product using this chemical name, which is the official generic designation for the compound.


Q: Does taking Baymite require regular blood monitoring?

Regulatory safety data focuses on observable signs of acute toxicity (such as tremor, paralysis, or convulsions). Regular blood monitoring is not explicitly mandated for the purpose of routine usage in the target species (livestock and poultry).


Q: What is the typical time frame for seeing the intended results of Baymite?

The product is classified as a contact insecticide and acaricide with a rapid initial effect on pest populations. It is intended for the quick knockdown of arthropods in the animal housing environments to manage infestation.


Q: What happens when Baymite is discontinued?

Research has been conducted to explore whether gradual dose reduction might affect the incidence or severity of discontinuation-related symptoms.


Q: What is the recommended period of use for Baymite treatment?

Official guidelines limit the number of applications in a single area to a maximum of two treatment cycles per year. This restriction is in place to help mitigate potential environmental impact.


Q: What are the long-term effects of taking Baymite?

Research related to the active ingredient has examined its long-term use in adults. The veterinary safety profile focuses on short-term toxicity signs, and the application is restricted to a maximum of two treatment cycles per year due to environmental constraints.


Q: What kind of specialist usually prescribes Baymite?

The product is a specialized veterinary ectoparasiticide intended for application by trained professionals. This includes veterinarians, pest control operators, or informed farmers who are acting under veterinary guidance.


Q: Does Baymite come in different strengths or forms (like a tablet or liquid)?

Baymite is supplied as a concentrate for spraying emulsion. This is a liquid form that must be freshly diluted with water immediately before external application. It is not available in systemic forms like tablets.


Q: Why do official documents state Baymite has a Black Box Warning?

The product's safety profile is formally classified due to its inherent toxicological properties as an organophosphorus compound. Serious adverse reactions associated with exposure include convulsions, paralysis, and death.


Q: Are there ongoing clinical trials related to Baymite?

Research has indicated that studies have not yet fully evaluated the agent in subjects with severe liver impairment. Furthermore, further research is examining the effects of renal impairment on the body's processing of the agent.


Q: How is Baymite different from supplements claiming similar effects?

Baymite's active ingredient, Phoxim, is classified as a highly potent synthetic chemical compound and an organophosphorus compound by regulatory authorities. This classification clearly differentiates it from herbal or dietary supplements.


Q: Can Baymite be taken on an empty stomach?

The drug is administered exclusively via the topical route as an external ectoparasiticide. Official documents state that it is not for internal or systemic use, meaning it is not intended to be taken by mouth.


Q: What types of allergic reactions are possible with Baymite?

Official documents contraindicate the product for animals with a known hypersensitivity to Phoxim or any component of the formulation. The active substance is also recognized as a skin sensitizer.

How should Baymite be stored and disposed of?

Official Storage Requirements

Regulatory labeling for Baymite (Phoxim Concentrate) defines precise storage conditions to maintain its stability and prevent accidental exposure.

  • Temperature and Light: Store the product securely, protected from direct sunlight and extremes of temperature, specifically below 40 C, and protect from freezing.
  • Container and Safety: The concentrate must be stored in its original container with the lid tightly closed. It must be kept out of the sight and reach of children and stored away from food, drink, and animal feed.

Stability and Disposal

The product's shelf-life after first opening is typically 6 months. Any diluted product has a limited stability period and must be used within 24 hours.

Disposal instructions mandate that unused product and waste materials must be disposed of in accordance with local requirements. The product is highly toxic to aquatic life; therefore, it must not be poured into watercourses or drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Baymite found in:

A-Z Index: